Cell and Gene Therapy Clinical Trials Market By Therapy Type (Cell Therapy {Autologous Cell Therapy, Allogeneic Cell Therapy, CAR-T Cell Therapy, Natural Killer Cell Therapy, Dendritic Cell Therapy, Stem Cell Therapy}, Gene Therapy {In-vivo Gene Therapy, Ex-vivo Gene Therapy}), By Phase (Phase I, Phase II, Phase III, Phase IV), By Disease Type (Oncology, Genetic Disorders, Neurological Disorders, Cardiovascular Diseases, Autoimmune Diseases, Infectious Diseases, Others), By Trial Sponsor (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions, Government and Non-Profit Organizations, Contract Research Organizations), By Gene Therapy Type (Viral Vector-based Gene Therapy {Adeno-associated Virus, Lentivirus, Retrovirus, Adenovirus}, Non-viral Vector-based Gene Therapy, Others), By Route of Administration (Intravenous, Intramuscular, Intrathecal, Intraocular, Subcutaneous, Others), and By End-User (Hospitals and Clinics, Academic and Research Institutes, Biopharmaceutical Companies, Contract Research Organizations, Others), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles, and Market Forecast, 2025 – 2035.

---

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & Forecast Parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Cell and Gene Therapy Clinical Trials Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. How does the increasing prevalence of rare genetic disorders stimulate global clinical research demand?

3.2.2. What impact do government incentives and funding have on advanced therapy development initiatives?

3.2.3. Why are biopharma companies prioritizing personalized treatments in regenerative and immune-modulating therapies?

3.3. Key industry pitfalls & challenges

3.3.1. What challenges do high operational costs pose to small biotech trial scalability worldwide?

3.3.2. How does complex regulatory compliance delay trial approvals across different regional jurisdictions?

3.3.3. Why is limited patient availability affecting recruitment rates in ultra-rare disease trials?

3.4. Market Opportunities

3.4.1. How can AI-based trial matching systems enhance protocol efficiency and patient enrollment accuracy?

3.4.2. Why is decentralized trial design gaining momentum across global cell therapy development programs?

3.4.3. What drives industry focus on allogeneic off-the-shelf therapies for scalable treatment delivery?

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Cell and Gene Therapy Clinical Trials Market, Therapy Type Segment Analysis

4.1. Overview of Dynamics

4.1.1. Market Revenue Share, By Therapy Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Cell Therapy

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.2. Autologous Cell Therapy

4.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.3. Allogeneic Cell Therapy

4.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.4. CAR-T Cell Therapy

4.2.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.5. Natural Killer Cell Therapy

4.2.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.6. Dendritic Cell Therapy

4.2.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.2.7. Stem Cell Therapy

4.2.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Gene Therapy

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.2. In vivo Gene Therapy

4.3.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3.3. Ex vivo Gene Therapy

4.3.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Cell and Gene Therapy Clinical Trials Market, Phase Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Phase, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Phase I

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. Phase II

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Phase III

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Phase IV

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Cell and Gene Therapy Clinical Trials Market, Disease Type Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Disease Type, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Oncology

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Genetic Disorders

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Neurological Disorders

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.5. Cardiovascular Diseases

6.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.6. Autoimmune Diseases

6.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.7. Infectious Diseases

6.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.8. Others

6.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Cell and Gene Therapy Clinical Trials Market, Trial Sponsor Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Trial Sponsor, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Pharmaceutical Companies

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Biotechnology Companies

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Academic and Research Institutions

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.5. Government and Non-Profit Organizations

7.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.6. Contract Research Organizations

7.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Cell and Gene Therapy Clinical Trials Market, Gene Therapy Type Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By Gene Therapy Type, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Viral Vector-based Gene Therapy

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.2.2. Adeno-associated Virus

8.2.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.2.3. Lentivirus

8.2.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.2.4. Retrovirus

8.2.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.2.5. Adenovirus

8.2.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Non-viral Vector-based Gene Therapy

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Others

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Cell and Gene Therapy Clinical Trials Market, Route of Administration Segment Analysis

9.1. Overview

9.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

9.1.2. Key Market Trends, Growth Factors, & Opportunities

9.2. Intravenous

9.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.3. Intramuscular

9.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.4. Intrathecal

9.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.5. Intraocular

9.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.6. Subcutaneous

9.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

9.7. Others

9.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

10. Cell and Gene Therapy Clinical Trials Market, End-user Segment Analysis

10.1. Overview

10.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

10.1.2. Key Market Trends, Growth Factors, & Opportunities

10.2. Hospitals and Clinics

10.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

10.3. Academic and Research Institutes

10.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

10.4. Biopharmaceutical Companies

10.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

10.5. Contract Research Organizations

10.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

10.6. Others

10.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

11. Cell and Gene Therapy Clinical Trials Market, Region Segment Analysis

11.1. Overview

11.1.1. Global Market Revenue Share, By Region, 2025 & 2035

11.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

11.2. North America

11.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

11.2.2. North America Market Revenue, By Therapy Type, 2025-2035

11.2.3. North America Market Revenue, By Phase, 2025-2035

11.2.4. North America Market Revenue, By Disease Type, 2025-2035

11.2.5. North America Market Revenue, By Trial Sponsor, 2025-2035

11.2.6. North America Market Revenue, By Gene Therapy Type, 2025-2035

11.2.7. North America Market Revenue, By Route of Administration, 2025-2035

11.2.8. North America Market Revenue, By End-user, 2025-2035

11.2.9. The U.S.

11.2.9.1. U.S. Market Revenue, By Therapy Type, 2025-2035

11.2.9.2. U.S. Market Revenue, By Phase, 2025-2035

11.2.9.3. U.S. Market Revenue, By Disease Type, 2025-2035

11.2.9.4. U.S. Market Revenue, By Trial Sponsor, 2025-2035

11.2.9.5. U.S. Market Revenue, By Gene Therapy Type, 2025-2035

11.2.9.6. U.S. Market Revenue, By Route of Administration, 2025-2035

11.2.9.7. U.S. Market Revenue, By End-user, 2025-2035

11.2.10. Canada

11.2.10.1. Canada Market Revenue, By Therapy Type, 2025-2035

11.2.10.2. Canada Market Revenue, By Phase, 2025-2035

11.2.10.3. Canada Market Revenue, By Disease Type, 2025-2035

11.2.10.4. Canada Market Revenue, By Trial Sponsor, 2025-2035

11.2.10.5. Canada Market Revenue, By Gene Therapy Type, 2025-2035

11.2.10.6. Canada Market Revenue, By Route of Administration, 2025-2035

11.2.10.7. Canada Market Revenue, By End-user, 2025-2035

11.3. Europe

11.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

11.3.2. Europe Market Revenue, By Therapy Type, 2025-2035

11.3.3. Europe Market Revenue, By Phase, 2025-2035

11.3.4. Europe Market Revenue, By Disease Type, 2025-2035

11.3.5. Europe Market Revenue, By Trial Sponsor, 2025-2035

11.3.6. Europe Market Revenue, By Gene Therapy Type, 2025-2035

11.3.7. Europe Market Revenue, By Route of Administration, 2025-2035

11.3.8. Europe Market Revenue, By End-user, 2025-2035

11.3.9. Germany

11.3.9.1. Germany Market Revenue, By Therapy Type, 2025-2035

11.3.9.2. Germany Market Revenue, By Phase, 2025-2035

11.3.9.3. Germany Market Revenue, By Disease Type, 2025-2035

11.3.9.4. Germany Market Revenue, By Trial Sponsor, 2025-2035

11.3.9.5. Germany Market Revenue, By Gene Therapy Type, 2025-2035

11.3.9.6. Germany Market Revenue, By Route of Administration, 2025-2035

11.3.9.7. Germany Market Revenue, By End-user, 2025-2035

11.3.10. France

11.3.10.1. France Market Revenue, By Therapy Type, 2025-2035

11.3.10.2. France Market Revenue, By Phase, 2025-2035

11.3.10.3. France Market Revenue, By Disease Type, 2025-2035

11.3.10.4. France Market Revenue, By Trial Sponsor, 2025-2035

11.3.10.5. France Market Revenue, By Gene Therapy Type, 2025-2035

11.3.10.6. France Market Revenue, By Route of Administration, 2025-2035

11.3.10.7. France Market Revenue, By End-user, 2025-2035

11.3.11. U.K.

11.3.11.1. U.K. Market Revenue, By Therapy Type, 2025-2035

11.3.11.2. U.K. Market Revenue, By Phase, 2025-2035

11.3.11.3. U.K. Market Revenue, By Disease Type, 2025-2035

11.3.11.4. U.K. Market Revenue, By Trial Sponsor, 2025-2035

11.3.11.5. U.K. Market Revenue, By Gene Therapy Type, 2025-2035

11.3.11.6. U.K. Market Revenue, By Route of Administration, 2025-2035

11.3.11.7. U.K. Market Revenue, By End-user, 2025-2035

11.3.12. Italy

11.3.12.1. Italy Market Revenue, By Therapy Type, 2025-2035

11.3.12.2. Italy Market Revenue, By Phase, 2025-2035

11.3.12.3. Italy Market Revenue, By Disease Type, 2025-2035

11.3.12.4. Italy Market Revenue, By Trial Sponsor, 2025-2035

11.3.12.5. Italy Market Revenue, By Gene Therapy Type, 2025-2035

11.3.12.6. Italy Market Revenue, By Route of Administration, 2025-2035

11.3.12.7. Italy Market Revenue, By End-user, 2025-2035

11.3.13. Spain

11.3.13.1. Spain Market Revenue, By Therapy Type, 2025-2035

11.3.13.2. Spain Market Revenue, By Phase, 2025-2035

11.3.13.3. Spain Market Revenue, By Disease Type, 2025-2035

11.3.13.4. Spain Market Revenue, By Trial Sponsor, 2025-2035

11.3.13.5. Spain Market Revenue, By Gene Therapy Type, 2025-2035

11.3.13.6. Spain Market Revenue, By Route of Administration, 2025-2035

11.3.13.7. Spain Market Revenue, By End-user, 2025-2035

11.3.14. Rest of Europe

11.3.14.1. Rest of Europe Market Revenue, By Therapy Type, 2025-2035

11.3.14.2. Rest of Europe Market Revenue, By Phase, 2025-2035

11.3.14.3. Rest of Europe Market Revenue, By Disease Type, 2025-2035

11.3.14.4. Rest of Europe Market Revenue, By Trial Sponsor, 2025-2035

11.3.14.5. Rest of Europe Market Revenue, By Gene Therapy Type, 2025-2035

11.3.14.6. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

11.3.14.7. Rest of Europe Market Revenue, By End-user, 2025-2035

11.4. Asia Pacific

11.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

11.4.2. Asia Pacific Market Revenue, By Therapy Type, 2025-2035

11.4.3. Asia Pacific Market Revenue, By Phase, 2025-2035

11.4.4. Asia Pacific Market Revenue, By Disease Type, 2025-2035

11.4.5. Asia Pacific Market Revenue, By Trial Sponsor, 2025-2035

11.4.6. Asia Pacific Market Revenue, By Gene Therapy Type, 2025-2035

11.4.7. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

11.4.8. Asia Pacific Market Revenue, By End-user, 2025-2035

11.4.9. China

11.4.9.1. China Market Revenue, By Therapy Type, 2025-2035

11.4.9.2. China Market Revenue, By Phase, 2025-2035

11.4.9.3. China Market Revenue, By Disease Type, 2025-2035

11.4.9.4. China Market Revenue, By Trial Sponsor, 2025-2035

11.4.9.5. China Market Revenue, By Gene Therapy Type, 2025-2035

11.4.9.6. China Market Revenue, By Route of Administration, 2025-2035

11.4.9.7. China Market Revenue, By End-user, 2025-2035

11.4.10. Japan

11.4.10.1. Japan Market Revenue, By Therapy Type, 2025-2035

11.4.10.2. Japan Market Revenue, By Phase, 2025-2035

11.4.10.3. Japan Market Revenue, By Disease Type, 2025-2035

11.4.10.4. Japan Market Revenue, By Trial Sponsor, 2025-2035

11.4.10.5. Japan Market Revenue, By Gene Therapy Type, 2025-2035

11.4.10.6. Japan Market Revenue, By Route of Administration, 2025-2035

11.4.10.7. Japan Market Revenue, By End-user, 2025-2035

11.4.11. India

11.4.11.1. India Market Revenue, By Therapy Type, 2025-2035

11.4.11.2. India Market Revenue, By Phase, 2025-2035

11.4.11.3. India Market Revenue, By Disease Type, 2025-2035

11.4.11.4. India Market Revenue, By Trial Sponsor, 2025-2035

11.4.11.5. India Market Revenue, By Gene Therapy Type, 2025-2035

11.4.11.6. India Market Revenue, By Route of Administration, 2025-2035

11.4.11.7. India Market Revenue, By End-user, 2025-2035

11.4.12. Australia

11.4.12.1. Australia Market Revenue, By Therapy Type, 2025-2035

11.4.12.2. Australia Market Revenue, By Phase, 2025-2035

11.4.12.3. Australia Market Revenue, By Disease Type, 2025-2035

11.4.12.4. Australia Market Revenue, By Trial Sponsor, 2025-2035

11.4.12.5. Australia Market Revenue, By Gene Therapy Type, 2025-2035

11.4.12.6. Australia Market Revenue, By Route of Administration, 2025-2035

11.4.12.7. Australia Market Revenue, By End-user, 2025-2035

11.4.13. South Korea

11.4.13.1. South Korea Market Revenue, By Therapy Type, 2025-2035

11.4.13.2. South Korea Market Revenue, By Phase, 2025-2035

11.4.13.3. South Korea Market Revenue, By Disease Type, 2025-2035

11.4.13.4. South Korea Market Revenue, By Trial Sponsor, 2025-2035

11.4.13.5. South Korea Market Revenue, By Gene Therapy Type, 2025-2035

11.4.13.6. South Korea Market Revenue, By Route of Administration, 2025-2035

11.4.13.7. South Korea Market Revenue, By End-user, 2025-2035

11.4.14. Singapore

11.4.14.1. Singapore Market Revenue, By Therapy Type, 2025-2035

11.4.14.2. Singapore Market Revenue, By Phase, 2025-2035

11.4.14.3. Singapore Market Revenue, By Disease Type, 2025-2035

11.4.14.4. Singapore Market Revenue, By Trial Sponsor, 2025-2035

11.4.14.5. Singapore Market Revenue, By Gene Therapy Type, 2025-2035

11.4.14.6. Singapore Market Revenue, By Route of Administration, 2025-2035

11.4.14.7. Singapore Market Revenue, By End-user, 2025-2035

11.4.15. Rest of Asia Pacific

11.4.15.1. Rest of Asia Pacific Market Revenue, By Therapy Type, 2025-2035

11.4.15.2. Rest of Asia Pacific Market Revenue, By Phase, 2025-2035

11.4.15.3. Rest of Asia Pacific Market Revenue, By Disease Type, 2025-2035

11.4.15.4. Rest of Asia Pacific Market Revenue, By Trial Sponsor, 2025-2035

11.4.15.5. Rest of Asia Pacific Market Revenue, By Gene Therapy Type, 2025-2035

11.4.15.6. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

11.4.15.7. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

11.5. Latin America

11.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

11.5.2. Latin America Market Revenue, By Therapy Type, 2025-2035

11.5.3. Latin America Market Revenue, By Phase, 2025-2035

11.5.4. Latin America Market Revenue, By Disease Type, 2025-2035

11.5.5. Latin America Market Revenue, By Trial Sponsor, 2025-2035

11.5.6. Latin America Market Revenue, By Gene Therapy Type, 2025-2035

11.5.7. Latin America Market Revenue, By Route of Administration, 2025-2035

11.5.8. Latin America Market Revenue, By End-user, 2025-2035

11.5.9. Brazil

11.5.9.1. Brazil Market Revenue, By Therapy Type, 2025-2035

11.5.9.2. Brazil Market Revenue, By Phase, 2025-2035

11.5.9.3. Brazil Market Revenue, By Disease Type, 2025-2035

11.5.9.4. Brazil Market Revenue, By Trial Sponsor, 2025-2035

11.5.9.5. Brazil Market Revenue, By Gene Therapy Type, 2025-2035

11.5.9.6. Brazil Market Revenue, By Route of Administration, 2025-2035

11.5.9.7. Brazil Market Revenue, By End-user, 2025-2035

11.5.10. Argentina

11.5.10.1. Argentina Market Revenue, By Therapy Type, 2025-2035

11.5.10.2. Argentina Market Revenue, By Phase, 2025-2035

11.5.10.3. Argentina Market Revenue, By Disease Type, 2025-2035

11.5.10.4. Argentina Market Revenue, By Trial Sponsor, 2025-2035

11.5.10.5. Argentina Market Revenue, By Gene Therapy Type, 2025-2035

11.5.10.6. Argentina Market Revenue, By Route of Administration, 2025-2035

11.5.10.7. Argentina Market Revenue, By End-user, 2025-2035

11.5.11. Mexico

11.5.11.1. Mexico Market Revenue, By Therapy Type, 2025-2035

11.5.11.2. Mexico Market Revenue, By Phase, 2025-2035

11.5.11.3. Mexico Market Revenue, By Disease Type, 2025-2035

11.5.11.4. Mexico Market Revenue, By Trial Sponsor, 2025-2035

11.5.11.5. Mexico Market Revenue, By Gene Therapy Type, 2025-2035

11.5.11.6. Mexico Market Revenue, By Route of Administration, 2025-2035

11.5.11.7. Mexico Market Revenue, By End-user, 2025-2035

11.5.12. Rest of Latin America

11.5.12.1. Rest of Latin America Market Revenue, By Therapy Type, 2025-2035

11.5.12.2. Rest of Latin America Market Revenue, By Phase, 2025-2035

11.5.12.3. Rest of Latin America Market Revenue, By Disease Type, 2025-2035

11.5.12.4. Rest of Latin America Market Revenue, By Trial Sponsor, 2025-2035

11.5.12.5. Rest of Latin America Market Revenue, By Gene Therapy Type, 2025-2035

11.5.12.6. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

11.5.12.7. Rest of Latin America Market Revenue, By End-user, 2025-2035

11.6. MEA

11.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

11.6.2. MEA Market Revenue, By Therapy Type, 2025-2035

11.6.3. MEA Market Revenue, By Phase, 2025-2035

11.6.4. MEA Market Revenue, By Disease Type, 2025-2035

11.6.5. MEA Market Revenue, By Trial Sponsor, 2025-2035

11.6.6. MEA Market Revenue, By Gene Therapy Type, 2025-2035

11.6.7. MEA Market Revenue, By Route of Administration, 2025-2035

11.6.8. MEA Market Revenue, By End-user, 2025-2035

11.6.9. GCC Countries

11.6.9.1. GCC Countries Market Revenue, By Therapy Type, 2025-2035

11.6.9.2. GCC Countries Market Revenue, By Phase, 2025-2035

11.6.9.3. GCC Countries Market Revenue, By Disease Type, 2025-2035

11.6.9.4. GCC Countries Market Revenue, By Trial Sponsor, 2025-2035

11.6.9.5. GCC Countries Market Revenue, By Gene Therapy Type, 2025-2035

11.6.9.6. GCC Countries Market Revenue, By Route of Administration, 2025-2035

11.6.9.7. GCC Countries Market Revenue, By End-user, 2025-2035

11.6.10. South Africa

11.6.10.1. South Africa Market Revenue, By Therapy Type, 2025-2035

11.6.10.2. South Africa Market Revenue, By Phase, 2025-2035

11.6.10.3. South Africa Market Revenue, By Disease Type, 2025-2035

11.6.10.4. South Africa Market Revenue, By Trial Sponsor, 2025-2035

11.6.10.5. South Africa Market Revenue, By Gene Therapy Type, 2025-2035

11.6.10.6. South Africa Market Revenue, By Route of Administration, 2025-2035

11.6.10.7. South Africa Market Revenue, By End-user, 2025-2035

11.6.11. Rest of Middle East & Africa

11.6.11.1. Rest of Middle-East & Africa Market Revenue, By Therapy Type, 2025-2035

11.6.11.2. Rest of Middle-East & Africa Market Revenue, By Phase, 2025-2035

11.6.11.3. Rest of Middle-East & Africa Market Revenue, By Disease Type, 2025-2035

11.6.11.4. Rest of Middle-East & Africa Market Revenue, By Trial Sponsor, 2025-2035

11.6.11.5. Rest of Middle-East & Africa Market Revenue, By Gene Therapy Type, 2025-2035

11.6.11.6. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

11.6.11.7. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

12. Company Profile

12.1. CRISPR Therapeutics AG

12.1.1. Business Overview

12.1.2. Financial Performance

12.1.3. Product/Service Offerings

12.1.4. Strategies & recent developments

12.1.5. SWOT Analysis

12.2. Vertex Pharmaceuticals Incorporated

12.2.1. Business Overview

12.2.2. Financial Performance

12.2.3. Product/Service Offerings

12.2.4. Strategies & recent developments

12.2.5. SWOT Analysis

12.3. Gilead Sciences, Inc.

12.3.1. Business Overview

12.3.2. Financial Performance

12.3.3. Product/Service Offerings

12.3.4. Strategies & recent developments

12.3.5. SWOT Analysis

12.4. Novartis AG

12.4.1. Business Overview

12.4.2. Financial Performance

12.4.3. Product/Service Offerings

12.4.4. Strategies & recent developments

12.4.5. SWOT Analysis

12.5. bluebird bio, Inc.

12.5.1. Business Overview

12.5.2. Financial Performance

12.5.3. Product/Service Offerings

12.5.4. Strategies & recent developments

12.5.5. SWOT Analysis

12.6. Sarepta Therapeutics, Inc.

12.6.1. Business Overview

12.6.2. Financial Performance

12.6.3. Product/Service Offerings

12.6.4. Strategies & recent developments

12.6.5. SWOT Analysis

12.7. Spark Therapeutics, Inc.

12.7.1. Business Overview

12.7.2. Financial Performance

12.7.3. Product/Service Offerings

12.7.4. Strategies & recent developments

12.7.5. SWOT Analysis

12.8. Editas Medicine, Inc.

12.8.1. Business Overview

12.8.2. Financial Performance

12.8.3. Product/Service Offerings

12.8.4. Strategies & recent developments

12.8.5. SWOT Analysis

12.9. Intellia Therapeutics, Inc.

12.9.1. Business Overview

12.9.2. Financial Performance

12.9.3. Product/Service Offerings

12.9.4. Strategies & recent developments

12.9.5. SWOT Analysis

12.10. Sana Biotechnology, Inc.

12.10.1. Business Overview

12.10.2. Financial Performance

12.10.3. Product/Service Offerings

12.10.4. Strategies & recent developments

12.10.5. SWOT Analysis

12.11. Beam Therapeutics Inc.

12.11.1. Business Overview

12.11.2. Financial Performance

12.11.3. Product/Service Offerings

12.11.4. Strategies & recent developments

12.11.5. SWOT Analysis

12.12. Verve Therapeutics, Inc.

12.12.1. Business Overview

12.12.2. Financial Performance

12.12.3. Product/Service Offerings

12.12.4. Strategies & recent developments

12.12.5. SWOT Analysis

12.13. Precision BioSciences, Inc.

12.13.1. Business Overview

12.13.2. Financial Performance

12.13.3. Product/Service Offerings

12.13.4. Strategies & recent developments

12.13.5. SWOT Analysis

12.14. Adaptimmune Therapeutics plc

12.14.1. Business Overview

12.14.2. Financial Performance

12.14.3. Product/Service Offerings

12.14.4. Strategies & recent developments

12.14.5. SWOT Analysis

12.15. Regenxbio Inc.

12.15.1. Business Overview

12.15.2. Financial Performance

12.15.3. Product/Service Offerings

12.15.4. Strategies & recent developments

12.15.5. SWOT Analysis